EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The 31-Gene Expression Profile Test Identifies Patients with AJCC T1a (<0.8mm) Cutaneous Melanoma at Increased Risk of 5-year Melanoma-Specific Mortality

Harrison Nguyen, Matthew Goldberg, Mark Gimbel, Jane Yoo, Abel Jarell, Eric Whitman

SKIN The Journal of Cutaneous Medicine · 10.03.2026 · 10 (2) · s754

DOI: 10.25251/t7y3ta94 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.03.2026. Verfasst von Harrison Nguyen und 5 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T1a cutaneous melanoma accounts for 75% of newly diagnosed tumors, with high associated survival rates (over 97% 5-year survival rates). However, a proportion of patients with T1a tumors do experience tumor recurrence and die from their disease. It is critically important, therefore, to identify the high-risk patients within this population considered low risk based on clinical or pathological features alone, as these high-risk patients would be expected to benefit from more extensive management (e.g., surveillance imaging, more frequent follow-up) and, thus, improve outcomes. The 31-gene expression profile (GEP) test stratifies risk of sentinel lymph node positivity, recurrence, metastasis, and death. Incorporating 31-GEP molecular tumor risk information with clinical and pathological staging factors can identify patients with a high risk of poor outcomes who may benefit from escalated clinical management to improve patient outcomes. We analyzed patients with T1a tumor clinically tested with the 31-GEP who were diagnosed between 2013–2019 linked to the SEER registry database and who had at least 5 years of follow up or died from their disease (n=750). Kaplan-Meier analysis was used to estimate 5-year melanoma-specific survival (MSS) rates, and differences between groups were compared using the log-rank test. Univariate analyses were conducted to identify predictors of melanoma-specific mortality. Among patients with T1a tumors, 88 out of 750 (11.7%) had non-Class 1A 31-GEP results. Patients with Class 2B or Class 1B/2A results had lower 5-year MSS than those with Class 1A results (86.2%, 88.1%, vs. 97.1%; p

Zitieren

APA

Nguyen, H., Goldberg, M., Gimbel, M., Yoo, J., Jarell, A., & Whitman, E. (2026). The 31-Gene Expression Profile Test Identifies Patients with AJCC T1a (. SKIN The Journal of Cutaneous Medicine, 10(2), s754. https://doi.org/10.25251/t7y3ta94

Vancouver

Nguyen H, Goldberg M, Gimbel M, Yoo J, Jarell A, Whitman E. The 31-Gene Expression Profile Test Identifies Patients with AJCC T1a (. SKIN The Journal of Cutaneous Medicine. 2026;10(2):s754. doi:10.25251/t7y3ta94

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Harrison and Goldberg, Matthew and Gimbel, Mark and Yoo, Jane and Jarell, Abel and Whitman, Eric},
  title = {The 31-Gene Expression Profile Test Identifies Patients with AJCC T1a (},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {2},
  pages = {s754},
  doi = {10.25251/t7y3ta94}
}
Kostenlos starten →